Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623467 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 343
- Enrollment target
NCT00623467 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 343 participants.
The verdict
NCT00623467, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 343 participants
- Enrollment target
Study Summary
This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Gadavist. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI will be compared to the results of images taken without Gadavist.
Interventions
- DRUG Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00623467
The ClinicalTrials.gov registry entry for NCT00623467 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gadobutrol (Gadavist, Gadovist, BAY86-4875) is the first listed.
NCT00623467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00623467 about?
NCT00623467 is a clinical study titled "Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging". This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Gadavist. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of th...
What is the current status of trial NCT00623467?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 343 participants. The study started on 2007-12. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00623467?
The interventions under investigation include: Gadobutrol (Gadavist, Gadovist, BAY86-4875) (DRUG).
Who is sponsoring clinical trial NCT00623467?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.